| NO | CODE | BIOASSAY | PHARMACOLOGICAL RELEVENCE | TURN AROUND TIME |
| 1. | CA01 |
| Lymphocyte proliferation |
| a. Naïve and LPS treated lymphocytes |
| b. Naïve and PHA induced |
| c. Naïve and Con A treated lymphocytes |
| d. Naïve and PWA induced |
| e. Naïve and anti-CD3 induced |
| Immune modulation | 4 weeks |
| 2. | CA02 | NO release | Immune modulation | 4 weeks |
| 3. | CA03 | NO scavenging | Anti-oxidant, Inflammation, Pain | 4 weeks |
| 4. | CA04 | Macrophage phagocytosis | Immune modulation | 4 weeks |
| 5. | CA05 | LTB4 release | Inflammation, Pain | 6 weeks |
| 6. | CA06 | Hepatoprotection using t-BH | Liver health | 4 weeks |
| 7. | CA08 | Histamine release | Inflammation, Allergy | 6 weeks |
| 8. | CA09 | Chromosomal aberration (OECD – 473) | Safety evaluation | 8 weeks |
| 9. | CA10 | Micronucleus (OECD – 487) | Safety evaluation | 8 weeks |
| 10. | CA11 | Melanin release using B16 | Skin Tanning / Lightning | 4 weeks |
| 11. | CA12 | PGE2 release | Inflammation, Pain | 4 weeks |
| 12. | CA13 | Insulin release | Diabetes | 4 weeks |
| 13. | CA14 | Collagen release | Wrinkle, Ageing | 6 weeks |
| 14. | CA15 | TXB2 release | Inflammation, Allergy, Pain | 4 weeks |
| 15. | CA16 | IL-1 beta inhibition + | Inflammation, Allergy | 6 weeks |
| 16. | CA17 | TNF alpha inhibition + | Inflammation, Allergy | 6 weeks |
| 17. | CA18 | AMES test (Bacterial Reverse Mutation) | Safety evaluation | 4 weeks |
| 18. | CA19 | IL-2 release (Con A induced)+ | Immune modulation | 6 weeks |
| 19. | CA20 | IL-4 release (Con A induced)+ | Immune modulation | 6 weeks |
| 20. | CA21 | IL-6 release (Con A induced)+ | Immune modulation | 6 weeks |
| 21. | CA22 | IFN gamma release (Con A induced)+ | Immune modulation | 6 weeks |
| 22. | CA23 | Neutral Red Uptake** | Cytotoxicity, CC50 correlation to acute oral rodent LD50, safety evaluation | 4 weeks |
| 23. | CA24 | Cellular antioxidant activity | General health, heart diseases | 4 weeks |
| 24. | CA25 | Hepatoprotection assay against diazinon (OPC) | Liver health | 4 weeks |
| 25. | CA26 | IL-6 inhibition+ | Inflammation | 6 weeks |
| 26. | CA27 | IL-2 release (PHA induced)+ | Immune modulation | 6 weeks |
| 27. | CA28 | IL-6 release (PHA induced)+ | Immune modulation | 6 weeks |
| 28. | CA29 | IL-2 release (PWA induced)+ | Immune modulation | 6 weeks |
| 29. | CA30 | IL-6 release (PWA induced)+ | Immune modulation | 6 weeks |
| 30. | CA31 | IL-2 release (Anti CD3 induced)+ | Immune modulation | 6 weeks |
| 31. | CA32 | IL-6 release (Anti CD3 induced)+ | Immune modulation | 6 weeks |
| 32. | CA33 | IL-2 release (LPS induced)+ | Immune modulation | 6 weeks |
| 33. | CA34 | IL-6 release (LPS induced)+ | Immune modulation | 6 weeks |
| 34. | CA35 | Hepatoprotection assay against Aldrin (OC) | Liver health | 4 weeks |